Prelude Therapeutics Incorporated (PRLD) Tuesday said it has entered into partnership with Merck to evaluate Prelude's PRT3789 combined with Merck's KEYTRUDA in Phase 2 study in patients with SMARCA4-mutated cancers.
As per the agreement, Merck will provide KEYTRUDA to Prelude, the sponsor of the Phase 2 combination study. Prelude and Merck retain all commercial rights to their respective compounds, including as monotherapy or as combination therapies.
PRT3789, a potent and highly selective, first-in-class SMARCA2 degrader, is currently in Phase 1 study in biomarker selected SMARCA4 mutant patients.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.